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Abstract
Background: Several reports indicate that a portion (5–10%) of men living with HIV-1 intermittently shed HIV-1 RNA into
seminal plasma while on long term effective antiretroviral therapy (ART). This is highly suggestive of an HIV-1 reservoir in
the male genital tract. However, the status of this reservoir in men living with HIV-1 who are not under treatment is
underexplored and has implications for understanding the origins and evolution of the reservoir.
Finding: Forty-three HIV-1 positive, antiretroviral therapy naïve study participants attending a men’s health clinic were
studied. Semen viral loads and blood viral loads were generally correlated, with semen viral loads generally detected in
individuals with blood viral loads > 10,000 cp/ml. However, we found 1 individual with undetectable viral loads (<20cp/ml)
and 2 individuals with very low blood viral load (97 and 333cp/ml), but with detectable HIV-1 in semen (485–1157 copies/
semen sample). Blood viral loads in the first individual were undetectable when tested three times over the prior 5 years.
Conclusions: Semen HIV-1 viral loads are usually related to blood viral loads, as we confirm. Nonetheless, this was not
true in a substantial minority of individuals suggesting unexpectedly high levels of replication in the male genital tract
in a few individuals, despite otherwise effective immune control. This may reflect establishment of a local reservoir of
HIV-1 populations.
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Introduction
Several reports in a range of settings globally indicate that
a portion (5–10%) of men living with HIV-1 intermit-
tently shed HIV-1 RNA into seminal plasma while on long
term effective antiretroviral therapy (ART) [1–5]. In a
series of observational studies, viral suppression with anti-
retroviral therapy is associated with no detectable risk of
transmission [6], even in populations of men having sex
with men with high rates of sexually transmitted infec-
tions and evidence for high rates of high risk sex [7]. The
reason that HIV-1 RNA shed into semen is not associated
with a detectable risk of transmission is unclear. Plausibly,
the proportion of virions that are viable in this context is
low [8] and thus an infectious dose of viable virions is not
reached. Nonetheless, the presence of HIV-1 RNA in
semen is highly suggestive of an HIV-1 reservoir in the
male genital tract [9]. However, the status of this reservoir
in men living with HIV-1 not under treatment is underex-
plored and has implications for understanding the origins
and evolution of the reservoir.
The presence of HIV-1 RNA during effective ART is
very likely indicative of persisting HIV-1 production in the
male genital tract because the half-life of HIV-1 virions in
serum is less than 8 h [10]. The reason production of
HIV-1 is able to persist in the male genital tract is not
clear. In some cases, penetration of ART drugs into the
male genital tract may be incomplete, but the picture is
complex and a simple association is not obvious [11].
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In this report, we studied men living with HIV-1 at a
Men’s clinic in Cape Town, South Africa who were not yet
on ART. We found individuals who were apparently cap-
able of suppressing their viral loads in the blood circulation,
but nonetheless did shed HIV-1 RNA into their semen.
Materials and methods
Study participants
Forty-three HIV-1 positive, ART-naive study participants
were recruited between June 2015 and January 2017 from
ANOVA Health’s Ivan Toms Health4Men clinics in
Woodstock, Green Point or Khayelitsha, all in Cape Town,
South Africa. Study participants were scheduled for sample
collection and interview when the clinic was otherwise
closed and were asked to abstain from sexual activity for
72 h prior to sample collection. For each study participant,
both blood and semen samples were collected during a sin-
gle visit. Study participants were interviewed and clinical
records were reviewed to identify current and recent sexu-
ally transmitted infections (STIs) and clinical history. Study
participants all self-reported to be ART naive and none pre-
viously received ART from Ivan Toms Health4Men clinics.
Sample handling and testing
The entire specimen of semen was diluted 1:1 with phos-
phate buffered saline (PBS) and then underlaid with 19%
Nycodenz (Axis-Shield PoC AS, Oslo, Norway) in PBS with
penicillin/streptomycin and centrifuged (1000 g, 20min) to
separate seminal plasma from sperm and other cells. Sem-
inal plasma was recovered, filtered (0.8 μm) and HIV-1 was
concentrated by centrifugation (100,000 g, 1 h 4 °C). The
pellet was resuspended in 200 μl of PBS, 40 μl of which was
diluted to 500 μl and assayed for viral load. The limit of de-
tection under these conditions was 100cp (copies)/ml, cor-
responding to 250cp/semen sample. Viral loads were
measured in a clinically accredited laboratory (National
Health Laboratory Service, Groote Schuur Hospital, Cape
Town) by the Roche COBAS AmpliPrep/TaqMan method-
ology. Blood samples were scored as undetectable only if
the viral load was undetectable at the time of collection and
also in a confirmatory test performed later on frozen blood
plasma.
Results and discussion
Median age was 29 years (IQR 25–36); median CD4 + T cell
count was 519 cells/μl (IQR 370–631), and median blood
viral load was 4.10 log10 cps/ml (IQR 2.69–4.56). Generally,
HIV-1 was detected in semen in samples with blood viral
load > 10,000cp/ml (Fig. 1) and for those samples, the log10
semen viral loads correlated moderately with the log10
blood viral loads (R2 = 0.1556, p = 0.026). This is in line with
previous studies showing a similar correlation, with thresh-
olds ranging from 2000 to 10,000cp/ml [12–16] (reviewed
in [17]). Some studies comparing blood to semen viral loads
had very few individuals with blood viral loads below 10,
000 cp/ml [18–20], possibly because they included many
individual with low CD4+ T cell counts.
The rough correlation between the two measures and
apparent threshold effect suggests that HIV-1 in the
male genital tract is ultimately fed from the larger HIV-1
populations in blood/general circulation (Kariuki SM, P.
S, Anthony A, Matten D, Abrahams MR, Martin DP,
Ariën KA, Rebe K, Williamson C, Dorfman JR:
Compartmentalization and clonal amplification of HIV-1
in the male genital tract characterized using next gener-
ation sequencing, submitted for publication). This is in
contrast to what is found by Klein et al [21] in the geni-
tal tracts of women with early stage HIV-1 infections.
There, the blood populations appeared to be derived
from those found in the genital mucosa. It is possible
that HIV-1 could reach the male genital tract from the
blood circulation in cases in which external male sex
Fig. 1 Display of blood viral load (cp/ml) vs semen viral load (cp/sample) for the 43 individual men in this study. Values plotted as 10cp/ml or
125cp/sample reflect undetectable viral loads. The red circle encloses the 3 individuals with detectable viral loads in semen but low or undetectable
viral loads in blood
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organs were the original site of inoculation. Additionally,
there may be differences in the site of the original HIV-1
inoculation in the participants in the present study, per-
haps due to high intravenous drug use in the population
from which our study participants were drawn [22] and/
or inoculation via the rectum. In such cases, HIV-1
reaching the male genital tract presumably did so via the
blood circulation.
More interestingly, we found 1 individual with undetect-
able viral loads (<20cp/ml) and 2 individuals with very low
blood viral load (97 and 333cp/ml), but with detectable
HIV-1 in semen, ranging from 485 to 1157 copies/semen
sample (Fig. 1). These did not fit the pattern of correlation
between blood and semen viral loads. The individual that
had undetectable blood viral load, had undetectable blood
viral loads when tested previously, approximately 3 and 5
years prior. CD4+ T cell counts of these three individuals
(range 403–1123 cells/μl) were not significantly different
from the other study participants (p = 0.14), nor was age
(p = 0.51). None of the three individuals reported sexually
transmitted infections (STIs) and no STIs were detected
upon clinical folder inspection or clinician interviews on
the day of sample collection. The small sample size pre-
vents meaningful statistical comparison.
The detection of HIV-1 viral loads in seminal plasma
in these individuals suggests that even highly effective
immune responses maintained for extended periods are
not always sufficient to suppress shedding of HIV-1
RNA into seminal plasma. A review of prior data reveal
that other studies may have observed one or two individ-
uals each with such patterns [12–16] (Figure S1). None
of these studies commented upon these individuals. A
recent report [23] studied 10 HIV-1 controllers and
measured secretion of HIV-1 RNA into seminal plasma.
HIV-1 RNA over 40 cp/ml in semen of the HIV-1 con-
trollers was detected, but only in individuals with rela-
tively high contemporaneous or 30-day prior blood viral
loads (685–5750 cp/ml). It thus seemed possible from
that study that the HIV-1 found in semen could have
been recently sourced from the systemic circulation.
Here, we describe individuals with lower contemporan-
eous blood viral loads, including one with three blood
viral loads below the detection limit over 5 years.
Individuals with an HIV-1 reservoir in the male genital
tract may be more common than we observe because (i)
they would be less obvious when reservoir-derived HIV-
1 RNA is intermingled with RNA from recent migrants
from robust HIV-1 populations in the blood circulation,
and because (ii) not all reservoirs necessarily give rise to
HIV-1 RNA secreted into semen at all times. In support
of the idea of the male genital tract as a potential reser-
voir, recent work has suggested that a substantial reser-
voir of HIV-1 persists during antiretroviral therapy in
urethral macrophages in the male genital tract [24].
Most study participants in the current study, including
the three individuals with this phenotype, received their pri-
mary care at the Ivan Toms clinic at which recruitment
took place, and none had been offered ART before the
samples were collected. All study participants were also
asked to confirm that they were not on ART. Additionally,
all three individuals with this phenotype were tested for
antiretroviral drugs in two ways: (i) serum of each individ-
ual was tested for the ability to inhibit entry and subsequent
gene expression of HIV-1 pseudotyped viruses expressing
the envelope of murine leukaemia virus (MLV) [25]; (ii)
blood plasma was tested for the presence of efavirenz and
lopinavir by liquid chromatography tandem mass spec-
trometry (LC MS/MS, qualitative test with limit of detec-
tion 0.02 μg/ml for both drugs). Efavirenz and boosted
lopinavir were the standard backbones for first and second
line ART, respectively, for adult men receiving ART in the
public sector in South Africa at the time of recruitment.
The limit of detection of the antiretroviral assays is consid-
erably lower than the minimum trough concentration
recommended for efficacy (1 μg/ml for both drugs [26]).
Antiretroviral drugs were not detected by either method.
The inability to inhibit MLV pseudotyped HIV-1 suggests
that no antiretroviral drug was present at functional con-
centrations. The LC MS/MS result indicates that it is highly
unlikely that efavirenz in normally prescribed doses was
taken in the 7 days prior to sample collection or lopinavir
in the 24 h prior to sampling. The time window is wider for
efavirenz because of its longer half-life [27].
The presence of HIV-1 RNA in seminal plasma of indi-
viduals whilst on ART has been better studied than in ART
naive individuals. HIV-1 is detectable in seminal plasma, at
least transiently, in approximately 5-10% of men living
with HIV-1 who were on ART with undetectable blood viral
loads [1–5]. This presence of HIV-1 RNA in semen of
ART-treated males is usually not associated with time since
ART initiation, suggesting that this was not simply a slower
decay of HIV-1 in semen compared to blood upon initiation
of ART. It is not clear if this is related by mechanism to the
HIV-1 shedding in semen of ART-naive individuals re-
ported here.
Generally, in individuals on ART with suppressed blood
viral loads (<200cp/ml), the presence of HIV-1 RNA in
semen is not associated with a detectable transmission
risk, even in MSM populations with high STI rates [7].
The results presented herein are nonetheless relevant to
understanding the potential tissue reservoirs of HIV-1.
What controls HIV-1 RNA shedding into semen is un-
clear. Although limited penetration of ART into the male
genital tract may play a role, the relationship appears com-
plex and partial [11] and does not play a role in the ART
naive individuals described in this report. Notably, in ART
treated males, the presence of HIV-1 RNA in seminal
plasma was associated with the presence of
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cytomegalovirus (CMV) DNA, in one study [3], but not an-
other [5]. Separately, congenital CMV infection, presum-
ably as a proxy measure for active CMV infection in the
placenta, is a strong risk factor (odds ratio = 20) for mother
to child transmission of HIV-1 in the face of widespread
maternal ART [28]. These associations between active
CMV infection and HIV-1 replication suggests that break-
through HIV-1 replication may have a biological basis
other than, or in addition to, poor penetration of ART
drugs.
Conclusion
That HIV-1 populations tend to be compartmentalized
between the general circulation and the male genital
tract is well established [29, 30]. Importantly, the results
presented here suggest that independent HIV-1 replica-
tion in the male genital tract sometimes occurs, resulting
in shedding of HIV-1 RNA into seminal plasma. Even
highly effective immune responses resulting in extended
periods with undetectable blood viral loads are not al-
ways sufficient to suppress this shedding. This replica-
tion could reflect that the male genital tract is the site of
a persistent HIV-1 reservoir.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: Figure S1. Correlation between semen and blood
viral load and presence of individuals with semen viral loads but low
blood viral loads in previously published data. All graphs generated from
table data in the reports except Olivier et al from supplemental figure 2B.
Tachet et al analyzed 52 individuals incl 21 on ART & did not identify
who was on ART. Red circles indicate individuals with low blood viral
loads and detectable HIV-1 RNA in semen. None of the reports commen-
ted on VL data from these individuals. Note that x-axis scales do not al-
ways match and that the y-axis scale for Olivier et al is different from the
other graphs. Graph from Olivier et al reprinted from J Infect Dis, 209,
1174–84 (2014), Olivier AJ et al, Distinct cytokine patterns in semen influ-
ence local HIV shedding and HIV target cell activation by permission of
Oxford University Press.
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